MTOR and type 2 diabetes mellitus: This study addressed the following issues regarding the therapeutic effect of dapagliflozin on T2DM-associated HFpEF: dapagliflozin (i) effectively prevents concentric hypertrophy, myocardial stiffness, and diastolic dysfunction in diabetic rat models, (ii) significantly mitigates the extent of cardiac nitro-oxidative stress, inflammation, and cardiomyocytes apoptosis, and (iii) enhances myocardial autophagic flux, possibly through an AMPK/mTOR-signaling pathway-dependent mechanism.